Gene delivery to dendritic cells by orally administered recombinant Saccharomyces cerevisiae in mice

Vaccine

Volumn 31, Issue 10, 2013, Pages 1360-1363

  Kiflmariam, Meron G ^a   Yang, Hanjiang ^a   Zhang, Zhiying ^a  

^a NORTHWEST A F UNIVERSITY   (China)

Author keywords

DNA delivery; Immune response; Oral; S. cerevisiae; Yeast

Indexed keywords

DNA VACCINE; GREEN FLUORESCENT PROTEIN; LIQUID NITROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOMEGALOVIRUS; DENDRITIC CELL; FLUORESCENCE MICROSCOPY; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SACCHAROMYCES CEREVISIAE; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES; CYTOMEGALOVIRUS; DENDRITIC CELLS; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; INTESTINAL MUCOSA; MALE; MICE; MICROSCOPY, FLUORESCENCE; PHAGOCYTOSIS; PROMOTER REGIONS, GENETIC; SACCHAROMYCES CEREVISIAE; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84875813110     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.048     Document Type: Article

References (35)

1. Walch B., Breinig T., Schmitt M.J., Breinig F. Delivery of functional DNA and messenger RNA to mammalian phagocytic cells by recombinant yeast. Gene Ther 2012, 19(March (3)):237-245.
2. Ryan R.M., Green J., Lewis C.E. Use of bacteria in anti-cancer therapies. Bioessays 2006, 28(January (1)):84-94.
3. Baban C.K., Cronin M., O'Hanlon D., O'Sullivan G.C., Tangney M. Bacteria as vectors for gene therapy of cancer. Bioeng Bugs 2010, 1(November-December (6)):385-394.
4. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(March (4949 Pt 1)):1465-1468.
5. Hickman M.A., Malone R.W., Lehmann-Bruinsma K., Sih T.R., Knoell D., Szoka F.C., et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994, 5(December (12)):1477-1483.
6. Wivel N.A., Wilson J.M. Methods of gene delivery. Hematol Oncol Clin North Am 1998, 12(June (3)):483-501.
7. Vassaux G., Nitcheu J., Jezzard S., Lemoine N.R. Bacterial gene therapy strategies. J Pathol 2006, 208(January (2)):290-298.
8. Emtage P.C., Wan Y., Hitt M., Graham F.L., Muller W.J., Zlotnik A., et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 1999, 10(March (5)):697-709.
9. Nasu Y., Bangma C.H., Hull G.W., Lee H.M., Hu J., Wang J., et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 1999, 6(March (3)):338-349.
10. Yamamoto M., Curiel D.T. Cancer gene therapy. Technol Cancer Res Treat 2005, 4(August (4)):315-330.
11. Cusack J.C., Tanabe K.K. Introduction to cancer gene therapy. Surg Oncol Clin N Am 2002, 11(July (3)):497-519. v.
12. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003, 21(March (3)):117-122.
13. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4(May (5)):346-358.
14. Blanquet S., Marol-Bonnin S., Beyssac E., Pompon D., Renaud M., Alric M. The 'biodrug' concept: an innovative approach to therapy. Trends Biotechnol 2001, 19(October (10)):393-400.
15. Underhill D.M. Macrophage recognition of zymosan particles. J Endotoxin Res 2003, 9(3):176-180.
16. Franzusoff A., Duke R.C., King T.H., Lu Y., Rodell T.C. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 2005, 5(April (4)):565-575.
17. Ballou C.E. A study of the immunochemistry of three yeast mannans. J Biol Chem 1970, 245(March (5)):1197-1203.
18. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004, 64(August (15)):5084-5088.
19. Franzusoff A., Schekman R. Functional compartments of the yeast Golgi apparatus are defined by the sec7 mutation. EMBO J 1989, 8(September (9)):2695-2702.
20. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7(May (5)):625-629.
21. Ardiani A., Higgins J.P., Hodge J.W. Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Res 2010, 10(December (8)):1060-1069.
22. Heintel T., Breinig F., Schmitt M.J., Meyerhans A. Extensive MHC class I-restricted CD8T lymphocyte responses against various yeast genera in humans. FEMS Immunol Med Microbiol 2003, 39(December (3)):279-286.
23. Wadle A., Held G., Neumann F., Kleber S., Wuellner B., Asemissen A.M., et al. Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. Vaccine 2006, 24(September (37-39)):6272-6281.
24. Howland S.W., Wittrup K.D. Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol 2008, 180(February (3)):1576-1583.
25. Blanquet S., Meunier J.P., Minekus M., Marol-Bonnin S., Alric M. Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment. Appl Environ Microbiol 2003, 69(May (5)):2884-2892.
26. Beier R., Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol 1998, 275(July (1 Pt 1)):G130-G137.
27. Haller A.A., Lauer G.M., King T.H., Kemmler C., Fiolkoski V., Lu Y., et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and core proteins. Vaccine 2007, 25(February (8)):1452-1463.
28. Bernstein M.B., Chakraborty M., Wansley E.K., Guo Z., Franzusoff A., Mostbock S., et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 2008, 26(January (4)):509-521.
29. Wansley E.K., Chakraborty M., Hance K.W., Bernstein M.B., Boehm A.L., Guo Z., et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 2008, 14(July (13)):4316-4325.
30. Boehm A.L., Higgins J., Franzusoff A., Schlom J., Hodge J.W. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother 2010, 59(March (3)):397-408.
31. Breinig F., Heintel T., Schumacher A., Meyerhans A., Schmitt M.J. Specific activation of CMV-primed human T lymphocytes by cytomegalovirus pp65 expressed in fission yeast. FEMS Immunol Med Microbiol 2003, 38(October (3)):231-239.
32. Gietz R.D., Woods R.A. Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006, 313:107-120.
33. Tabares E., Marcotegui M.A., Fernandez M., Sanchez-Botija C. Proteins specified by African swine fever virus. I. Analysis of viral structural proteins and antigenic properties. Arch Virol 1980, 66(2):107-117.
34. Owais M., Masood A.K., Agrewala J.N., Bisht D., Gupta C.M. Use of liposomes as an immunopotentiating delivery system: in perspective of vaccine development. Scand J Immunol 2001, 54(July-August (1-2)):125-132.
35. Michael A., Romanos, Carol A., Scorer, Jeffery J. Clare foreign gene expression in yeast: a review. Yeast 1992, 8:423-488.